文献速递脑血管病

既往再灌注策略不改变ELAN试验中早期与晚期抗凝结局

Prior Reperfusion Strategy Does Not Modify Outcome in Early Versus Late Start of Anticoagulants in Patients With Ischemic Stroke: Prespecified Subanalysis of the Randomized Controlled ELAN Trial.
PubMed 文献 · Stroke · 2025-05-22

ELAN试验预设亚组分析纳入1973例非瓣膜性房颤急性缺血性卒中患者,按既往再灌注治疗分为无再灌注、静脉溶栓、血管内治疗及静脉溶栓联合血管内治疗四组,未发现再灌注策略与早期或晚期启动直接口服抗凝药之间存在交互作用。

要点

  • 既往再灌注治疗(无、静脉溶栓、血管内治疗、联合)不影响早期与晚期启动DOAC的疗效。
  • 早期启动DOAC在无再灌注、血管内治疗及联合组的事件率数值上较低,但交互作用无统计学意义。
  • 静脉溶栓组早期启动DOAC事件率数值上高于晚期组(3% vs 2%),交互作用亦无统计学意义。

核心结论

  • 既往再灌注治疗不改变早期与晚期启动DOAC对房颤急性缺血性卒中患者临床结局的影响。

研究设计与样本

  • ELAN随机对照试验的事后分析,纳入有再灌注治疗数据的1973/2013例(98%)患者,中位年龄77(71-84)岁,女性899例(46%)。

主要发现

  • 未发现既往再灌注治疗与DOAC启动时机之间在任何结局事件上存在交互作用。
  • 无再灌注组早期DOAC事件率3.3%(17例)vs 晚期4.8%(24例),调整OR 0.69(95%CI 0.36-1.28)。
  • 血管内治疗组早期DOAC事件率1.2%(1例)vs 晚期6.4%(7例),调整OR 0.25(95%CI 0.03-1.21)。
  • 血管内治疗联合静脉溶栓组早期DOAC事件率2.4%(3例)vs 晚期3.3%(4例),调整OR 0.76(95%CI 0.17-3.23)。
  • 静脉溶栓组早期DOAC事件率3%(8例)vs 晚期2%(5例),调整OR 1.52(95%CI 0.52-4.84)。

临床怎么用

  • 对于房颤急性缺血性卒中患者,无论是否接受再灌注治疗,早期启动DOAC的策略可考虑用于临床决策。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early initiation of direct oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation and acute ischemic stroke is beneficial and safe. Whether prior acute reperfusion therapy modifies the treatment effect of early versus late DOAC initiation is unknown. METHODS: For this post hoc analysis of the multicenter, randomized controlled ELAN trial (Early Versus Late Initiation of Direct Oral Anticoagulants in Post-Ischaemic Stroke Patients With Atrial Fibrillation), all participants with data concerning reperfusion treatment were included. The primary outcome was the composite outcome of recurrent ischemic stroke, symptomatic intracranial hemorrhage, major extracranial bleeding, systemic embolism, or vascular death within 30 days. Patients were divided into 4 groups based on prior reperfusion therapy: no treatment, intravenous thrombolysis (IVT), endovascular treatment (EVT), or IVT combined with EVT. We performed logistic regression adjusted for age, hypertension, infarct location/size, pre-modified Rankin Scale, NIHSS, and hemorrhagic transformation, including the interaction term between treatment groups (early versus late DOAC) and reperfusion strategy. RESULTS: We included 1973 of 2013 (98%) patients of the ELAN trial population, with a median age of 77 (71-84) years and of whom 899 (46%) were female. Of them, 1015 (51%) underwent no prior reperfusion treatment, 519 (26%) IVT, 190 (10%) EVT, and 249 (13%) IVT+EVT. We did not identify an interaction for any of the outcome events between prior reperfusion therapy and timing of DOAC initiation. Rates were numerically lower in the early DOAC-initiated group for the following: no reperfusion therapy, 17 (3.3%) versus 24 (4.8%; adjusted odds ratio, 0.69 [95% CI, 0.36-1.28]); EVT, 1 (1.2%) versus 7 (6.4%; adjusted odds ratio, 0.25 [95% CI, 0.03-1.21]); and EVT+IVT, 3 (2.4%) versus 4 (3.3%; adjusted odds ratio, 0.76 [95% CI, 0.17-3.23]). In patients who had received IVT, the rates were 3% (n=8) in the early group versus 2% (n=5) in the late group (adjusted odds ratio, 1.52 [95% CI, 0.52-4.84]). CONCLUSIONS: Prior reperfusion therapy does not modify the effect of early versus late DOAC initiation on clinical outcomes in patients with atrial fibrillation and acute ischemic stroke. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03148457.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Wouters A, Demeestere J, Rossel JB, et al. Prior Reperfusion Strategy Does Not Modify Outcome in Early Versus Late Start of Anticoagulants in Patients With Ischemic Stroke: Prespecified Subanalysis of the Randomized Controlled ELAN Trial. Stroke. 2025. PMID: 40402090. doi:10.1161/STROKEAHA.125.050646

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。